DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
The committee will discuss biologics license application (BLA) 761143, teprotumumab solution for intravenous use, submitted by Horizon Pharma Ireland, Ltd., proposed for the treatment of active thyroid eye disease.
The public participation information has been changed for the December 13, 2019 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee. The deadline for making formal oral presentation requests has been changed from Tuesday, November 26, 2019 to Monday, December 2, 2019. The deadline for submitting electronic or written comments to be provided to the committee has been changed from Wednesday, December 4, 2019 to Monday, December 9, 2019.
Date & Time:
December 13, 2019
8:00 AM to 4:00 PM
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31 Conference Center
The Great Room (Rm. 1503)
Silver Spring, Maryland, United States
This event has ended.
Videos & VisualsChristina’s Thyroid Eye Disease Journey – Dr. Raymond Douglashttps://www.youtube.com/watch?v=XM3Yq43x...
News & MeetingsFDA Approves First Treatment for Thyroid Eye Disease (Teprotumumab)The U.S. Food and Drug Administration (F...
Evidence & EducationLong-Term Outcomes of Orbital Fat Decompression in Graves’ OrbitopathyPurpose: To evaluate the long-term clin...
Evidence & EducationKnowledge of Thyroid Eye Disease in Graves’ Disease Patients With and Without OrbitopathyBackground: Thyroid eye disease (TED) d...
People & PlacesRaymond Douglas, MD, PhDDr. Raymond Douglas is the Director of t...
News & MeetingsFDA Committee Unanimously Recommends Approval of Teprotumumab for Thyroid Eye DiseaseThe Dermatologic and Ophthalmic Drugs Ad...
Evidence & EducationRelation between Therapy Options for Graves’ Disease and the Course of Graves’ Ophthalmopathy: A Systema...Background: The relation between therap...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.